FDA

FDA Accuses Companies Of Marketing Cannabis Products To Children Amid Debate On Hemp Cannabinoids Ban
Bipartisan Effort At U.S. Capitol Calls On FDA To Approve MDMA Therapy For Vets And Others With PTSD
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Bipartisan Effort At U.S. Capitol Calls On FDA To Approve MDMA Therapy For Vets And Others With PTSD
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
FDA Committee 'Completely Lost Sight Of The Big Picture' Says Retired Lieutenant General Urging Approval On MDMA For PTSD
FDA Selects Moderna's Rare Disease Candidate For Accelerated Development Program

FDA Recent News

Top Federal Drug Official Praises Psychedelics' Potential, Psilocybin And Ketamine On City Health Plans And More
NIDA Director praises psychedelics, NCCIH highlights psilocybin's benefits and Atlanta explores adding psilocybin, ketamine to health plans.
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic competition.
NJ Activists Plant Cannabis Garden On State House Lawn, Fentanyl Replaces MDMA In Fed Drug Testing, Psychedelics Therapy For Vets
NJ activists defy laws with a cannabis garden, Congress advocates MDMA therapy for vets, and fentanyl replaces MDMA in federal tests. Read!
FDA Commissioner To House Committee: 'There's No Reason For DEA To Delay' Cannabis Rescheduling
FDA Commissioner Robert Califf faced questions on various critical issues at a House Oversight hearing, including the rescheduling of cannabis and FDA's decision not to regulate CBD as a food and dietary supplement.
U.S. Hemp Authority Announces Quality Seal Certification For Delta-8 THC
Delta-8 market is in the spotlight again as the Hemp Authority industry initiative announces its plan to certify the quality of this substance with a seal.
FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring
FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease. Availability is slated for April in the U.S.
GOP Sen. John Cornyn Takes Health Secretary To Task Over Cannabis Rescheduling: Xavier Becerra Holds His Own
Texas Sen. Cornyn took issue with the thoroughness of the scientific scrutiny cannabis, which was directed by President Biden.
US Health Agency Reviews Novo Nordisk's Wegovy For Potential Use In Treating Heart Disease Patients With Obesity
The CMS is reviewing the FDA's action to expand use of Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
The credibility of the clinical trial results for an experimental Alzheimer's drug has been called into question following a critical inspection report by the Food and Drug Administration.
FDA Gathers Public Social Media Data To Better Understand Cannabis Users As Part Of Its Effort Toward Rescheduling Marijuana
For six months, social scientists immersed themselves in a detailed analysis of online and social media conversations around cannabis.
Politics Over Public Health? FDA Head Expresses Concern Over Biden's Delay Of Menthol Cigarette Ban
FDA Commissioner Califf raises concerns about political interference in Biden's health policies, especially regarding a nationwide menthol cigarette ban.
Marjorie Taylor Greene Faces Democratic Criticism Over 'Vulgarity' And 'Conspiracy' In Vaccine Hearing
Greene, who is not a medical professional, claimed to have a "Ph.D. in recognizing bullshit" during a hearing on vaccine safety and public trust in vaccinations.
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday second quarter financial results for the three months ended Dec. 31, 2023, The company's primary focus is on developing therapy for acute cannabinoid intoxication (ACI).Total operating expenses in the second quarter of fiscal 2024 were $2.8 million compared with $3.8 million in the same period in fiscal 2023.Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.
FDA Approves Hemp Meal For Hen Feed, NH Eyes Private Cannabis Sales Model, CT Flower Shortage And More
Explore groundbreaking FDA approval for hemp seed meal in hen diets, plus key cannabis regulatory updates across the US, from Maine to Iowa.
Why Obesity-Drug Maker NeuroBo Stock Is Trading Higher
NeuroBo announced that the FDA has cleared its IND application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of 2024.
USDA Intensifies Hemp Industry Analysis With Nationwide Farmer Surveys
USDA's hemp survey reveals industry insights, challenges, and economic potential. Explore the future of hemp amid regulatory changes.
FDA Finds No Evidence Weight-Loss Drugs Cause Suicidal Thoughts
The FDA released an update on Thursday stating that its preliminary review did not find definitive evidence that the drugs cause suicidal thoughts or actions. However, the FDA investigation will continue because a link could not be ruled out to due the small number of suicidal thoughts or actions observed in both people using the drugs and in the comparative control groups. 
Reckitt's Mead Johnson Initiates Massive Recall Of 675K Cans Of Hypoallergenic Baby Formula Over Bacteria Contamination Fears
A massive recall of hypoallergenic infant formula has been initiated due to concerns over potential bacteria contamination. The recall involves approximately 675,000 cans of infant formula.
Charlotte's Web And DeFloria Launch First Ever Hemp-Based Drug Into Human Trials
DeFloria and Charlotte's Web launch Phase 1 clinical trial of hemp-based drug AJA001. Explore safety, benefits, and future prospects.
CBD's Critical Moment: Coalition Pushes For FDA Oversight
Explore the urgent need for FDA regulation in the hemp industry, as ONE HEMP coalition advocates for clear, safe CBD product standards.
Logan Paul Challenges Schumer's Scrutiny Of PRIME's Caffeine Content: 'Why Aren't We Controlling This At The Point Of Purchase?'
Elon Musk's Brain Chip Company Gets FDA Greenlight For 'First-In-Human Clinical Study'
Tesla, Apple, Riot Platforms, AMC, Emergent Biosolutions: Why These 5 Stocks Are Drawing Investors' Attention Today
U.S.